{
    "root": "348b0d24-a89c-3f4e-e063-6394a90a183d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amoxicillin and Clavulanate Potassium",
    "value": "20250507",
    "ingredients": [
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "AMOXICILLIN",
            "code": "804826J2HU"
        },
        {
            "name": "CLAVULANATE POTASSIUM",
            "code": "Q42OMW3AT8"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "ETHYLCELLULOSES",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        }
    ],
    "indications": "Amoxicillin and Clavulanate Potassium Tablets are indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below:\n                  \n                     \n                        Lower Respiratory Tract Infections-caused by beta‑lactamase‑producing isolates of\n  \n   Haemophilus influenzaeand\n  \n   Moraxella catarrhalis.\n \n  \n                     \n                        Acute Bacterial Otitis Media-caused by beta‑lactamase‑producing isolates of\n  \n   H. influenzaeand\n  \n   M. catarrhalis.\n \n  \n                     \n                        Sinusitis-caused by beta‑lactamase‑producing isolates of\n  \n   H. influenzaeand\n  \n   M. catarrhalis.\n \n  \n                     \n                        Skin and Skin Structure Infections-caused by beta‑lactamase‑producing isolates of\n  \n   Staphylococcus aureus,\n  \n   Escherichia coli, and\n  \n   Klebsiellaspecies.\n \n  \n                     \n                        Urinary Tract Infections-caused by beta‑lactamase‑producing isolates of\n  \n   E. coli,\n  \n   Klebsiellaspecies, and\n  \n   Enterobacterspecies.\n \n  \n                  \n                  \n                     Limitations of Use\n                       When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, Amoxicillin and Clavulanate Potassium Tablets should not be used.\n\n \n                  \n                     Usage\n                       To reduce the development of drug‑resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium Tablets and other antibacterial drugs, Amoxicillin and Clavulanate Potassium Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications": "Adults and Pediatric Patients greater than 40 kg: 875 mg every 12 hours, based on amoxicillin component. ( 2.2 , 2.3 )",
    "warningsAndPrecautions": "Amoxicillin and Clavulanate Potassium Tablets USP, 875mg/125mg: Each scored Off-white film coated capsule-shaped tablet, debossed with WW949 on the upper side and bisected on the other side, contains 875 mg amoxicillin as the trihydrate and 125 mg clavulanic acid as the potassium salt (equivalent to 149 mg of clavulanate potassium).\n                  \n                  \n                  NDC: 70518-4148-00\n                  NDC: 70518-4148-01\n                  NDC: 70518-4148-02\n                  NDC: 70518-4148-03\n                  NDC: 70518-4148-04\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 20 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 14 in 1 BLISTER PACK \n                  \n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].\n                  Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).\n                  Advise patients to keep in a closed container.\n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.\n                  \n                  \n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to Amoxicillin and Clavulanate Potassium Tablets or to other beta-lactams (e.g., penicillins or cephalosporins). ( 4.1 ) History of cholestatic jaundice/hepatic dysfunction associated with Amoxicillin and Clavulanate Potassium Tablets ( 4.2 )"
}